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dependence on the responsiveness of the RWD holder. Further, the findings un-
derscore limited feasibility for assessing outcomes in anti-diabetic drugs without
database linkage, suggesting the need for improved RWDs in Europe.
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OBJECTIVES: To compare the completeness of maternity data from a primary care
database, The Health Improvement Network (THIN), and a secondary care data-
base, Hospital Episodes Statistics (HES). METHODS: From 1998-2009, 2,649 preg-
nancies were identified from one practice in THIN. A group of 15,166 patients in the
same practice was linked to secondary care data from HES and 3,285 pregnancies
were identified from this population. The completeness of recording for maternity
variables within each dataset was compared. RESULTS:Maternal age was recorded
for all pregnancies in both datasets and a measure of social deprivation was re-
corded for over 95% of pregnancies in THIN and HES. Ethnicity recording in THIN
was inconsistent with 56.4% missing or unknown, whilst in HES it was recorded for
75.1% of pregnancies. In THIN, 0.2% of pregnancies had data on the number of
babies compared to 94% of pregnancies in HES. In both datasets, less than 25% of
pregnancies had the number of previous pregnancies recorded. In HES, over 60% of
pregnancies contained data on birth weight, sex of the baby and mode of delivery
compared to fewer than 7% of pregnancies in THIN. Gestational age at birth was
recorded for less than half of pregnancies in both THIN and HES. CONCLUSIONS:
These maternity data are better recorded in HES than in THIN, suggesting possible
benefits from linking the two data sources – primary care provides clinical infor-
mation e.g. medical conditions and prescriptions, whilst secondary care provides
data on pregnancy and birth outcomes. These findings are currently limited to one
practice. Future work includes examining the baby’s records in THIN and HES for
further data, assessing other variables, such as non-live birth outcomes, and ex-
panding the analysis to a larger dataset of THIN-HES linked practices.
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OBJECTIVES: To evaluate the costs and outcomes of two Benign Prostatic Hyper-
plasia (BPH) surgical procedures available in the public health care system in Brazil.
METHODS: A 3-year longitudinal analysis (2009 to 2011) of an anonymized govern-
ment administrative database (Inpatient Information System - SIH/DATASUS) was
performed. The study cohort comprised all BPH hospitalization registries (ICD10
D299 and N40) from male patients and aged 40 years and over. Patients were
uniquely identified by the following parameters: date of birth, postal code, gender
and ethnicity. Deterministic registry matching was applied. Costs were reported in
2012 Brazilian currency (1BRL0.52USD). Outcomes assessed were reoperation
rates, average in-hospital length-of-stay (in days), and need for intensive care unit
(ICU). Descriptive statistics [i.e., average, standard deviation (SD) and proportions]
summarized studied data. RESULTS: A total of 48,750 patients with average age of
68.38.6 were identified within 3 years of analysis. 21,747 patients were submitted
to SP (total cost BRL27.9 million) and 27,003 to TURP (total cost BRL22.0 million).
There were different proportions of surgical types among Brazilian regions, SP and
TURP, respectively: North (N) 69.5% vs. 30.5%, Northeast (NE) 57.7% vs. 42.3%, Cen-
tral West (CE) 43.3% vs. 58.7%, South (S) 41.3% vs. 58.7% and Southeast (SE) 32.6% vs.
67.4%. SP was linked with longer in-hospital length-of-stay (6.455.29) versus TURP
(3.954.31) and also with an increased proportion of procedures requiring ICU 4.2%
and 2.6%. The rate of reoperation was 0.5% in SP and 1.8% in TURP patients.
CONCLUSIONS: SP compared with TURP procedure was linked with more costs to
public health care system in Brazil, a higher need for ICU utilization and increased
days of hospitalization. Nevertheless, reoperation rates following SP were lower
than TURP. A higher number of SP procedures in different Brazilian regions may be
related to availability/access/discrepancies in the treatment of BPH, lack of tech-
nology and under diagnose.
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OBJECTIVES: To evaluate hospitalization registry and disease costs of benign pros-
tatic hyperplasia (BPH) patients in the public health care system in Brazil.
METHODS: A 3-year longitudinal analysis (2009 to 2011) of an anonymized govern-
ment administrative database (Inpatient Information System - SIH/DATASUS) was
performed. Patients with at least one BPH registry (ICD10 D291/N40) were uniquely
identified by the following parameters: date of birth, postal code, gender, and eth-
nicity and followed over the analysis period to find events associated with BPH.
Patients with prostate/bladder cancer were excluded. Deterministic registry
matching procedures were applied. Costs were reported in 2012 Brazilian currency
(1BRL0.52USD). Outcomes assessed were rehospitalization rates, age and ethnic-
ity distribution. Descriptive statistics [i.e., average, standard deviation (SD) and
proportions] summarized studied data. RESULTS: A total of 55,123 patients (aver-
age 68.48.8 years) were identified throughout the analysis. Age distribution was
15.6% 59 years, 74% 60-79 and 10.4% 80. Ethnicity distribution was: 36.5%
whites, 24.8% Latin, 3.8% Black, 1.1% others and 33.7% without information. Most
patients were admitted to hospital for BPH surgical procedures (88.4%). Percentage
of a second hospitalization due to BPH was 9.9%. Other 2.5% required three or more
hospitalizations. Percentage of total hospitalizations and total costs for BPH asso-
ciated events were: Acute Urinary Retention (AUR): 2.6% and 1.9%, Urinary Tract
Infection (UTI): 2.6% and 1.3%, Urethral Stenosis: 1.9% and 1.0%, Infection and
Inflammation: 0.8% and 0.3%, Renal Failure 0.7% and 1.2% and Others: 2.4% and
2.8%. Total cost was BRL60,7 million (BRL20million yearly) with an average cost of
BRL1,100/patient/year, with age group variations of BRL889 in 40-49 years to
BRL1,147 in 70-79 years. Total cost with BPH associated events was BRL5,1million.
CONCLUSIONS: In Brazil, BPH patients are more frequently hospitalized in age
group 60-79 with a 3-year rehospitalization rate reaching 12.4%. AUR and UTI rep-
resented the most frequent and costly BPH associated events.
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OBJECTIVES: Dabigatran is indicated to reduce stroke/ systemic embolism risk in
patients with non-valvular atrial fibrillation (AFIB). Post approval, there has been
much focus on dabigatran safety. Thus, we evaluated dabigatran real world use
and safety in the United States in the context of approved labeling relating to
safety. METHODS: A retrospective evaluation was conducted of de-identified,
pharmacy/medical claims in patients with a new dabigatran prescription claim
during 11/2010-08/2011 and continuous eligibility of 12 months prior and 4-months
after initiation of treatment. Demographic/clinical characteristics of patients, pre-
scriber specialty, and adoption of approved labeling recommendations (renal func-
tion testing, drug interactions, and dosage recommendations) were assessed.
RESULTS: A total of 1,424 patients, mostly males (61.5%), 7311 years old, received
a dabigatran dose of 150mg BID (93.8%), prescribed primarily by a cardiologist
(60.7%). In regards to label guidance, 1090 (77%) patients had a claims history for
AFIB, 19.2% were exposed to medications that increase the serum concentration of
dabigatran, and 20.2% were exposed to medications listed as inhibitors of dabiga-
tran metabolism. Renal function assessment within the prior year was evident in
22.8% of patients (11.3% in pts 75 years old), and over 4 months of f/u in 12.3%
(6.1% in pts 75 years old). Additionally, only 48.8% of patients with a creatinine
clearance 30 mL/min received 75 mg BID. CONCLUSIONS: Despite specific dab-
igatran labeling recommendations, a high percentage of prescribers are not follow-
ing the guidance for: indications; dosage adjustment for interacting drugs, renal
function, or age; or, renal function monitoring, which may adversely affect stroke
or bleeding outcomes. Ongoing review and action on dabigatran prescribing and
monitoring to optimize safe clinical outcomes in a real world population are
needed.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug and medical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database that gathers details of Post-Marketing Requirements (PMRs), i.e., studies
requested by the following regulatory agencies: European Medicines Agency (EMA,
EU); the Food and Drug Administration (FDA, USA); and the Haute Autorité de Santé
(HAS, France). METHODS: All drug approvals published by the EMA, the FDA, and
the HAS between January 1, 2005 and December 31, 2011 were reviewed to retrieve
PMRs. The information was categorized as follows: product description (brand
name, INN, indication, etc.); application details; PMR details; and information
source. RESULTS: For the FDA, we reviewed 763 original approvals and 944 supple-
ments and included, respectively, 201 and 110 drugs approved with PMRs. For the
EMA, we reviewed 349 marketing authorizations and included 38 files with PMRs.
For the HAS, 3674 opinions were published with only 174 opinions with PMRs. Many
HAS requests were long-term follow-up studies. About 43% of the PMRs requested
by the FDA were pediatric studies. At present, the EMA also requires pediatric
studies but under a Pediatric Investigation Plan (PIP). Since 2005, 21 PIPs have been
requested. No matter which agency is reviewed, all kinds of indications are covered
by the PMRs, e.g., treatment of sepsis, asthma, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about PMRs requested in Europe and in the USA. It will be useful to observe the
trends in studies requested, to anticipate the demands, and to integrate the studies
as early as possible in the product development process. The Post-Marketing Re-
quirements database will be available online in an independent website, with ac-
cess by subscription.
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OBJECTIVES: Clinical trials remain the gold standard for proving efficacy but re-
strictive enrolment criteria and overly controlled study environments limit gener-
alizability. Increasingly, payers and health care providers are interested in real
world evidence to support the case for pharmaceutical innovations. We review
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several sources of real world data available to researchers.METHODS:We compare
and contrast the pros and cons of data available from administrative (payment)
databases, electronic medical record (EMR) databases, and surveys. RESULTS: Ad-
ministrative claims databases provide fully-integrated, all-encounter patient data
on diagnoses, procedures, and payments. However, data quality varies depending
upon whether particular fields are required for provider payment. Data on lab and
test values are typically lacking. Prescriptions that are written, but not filled by the
patient, are usually not captured. Medical record data overlap, to a certain extent,
with administrative data. While information on payments for services may not be
included, detailed information on test results and lab values are usually captured
in the EMR. Data are included on written prescriptions, but the researcher will not
know whether the prescription was filled by the patient. Depending upon the clin-
ical system covered, only some encounters (e.g., ambulatory care in the outpatient
setting) may be available. Both administrative and EMR data hold the potential to
provide longitudinal patient information that is not subject to recall or social de-
sirability biases that often affect survey data. However, information on satisfaction
with care, quality of life, activities of daily living, and many other metrics, may only
be captured with survey data. CONCLUSIONS: Several sources of rich, longitudinal
patient data are available to provide real world evidence on drug effectiveness and
cost. In some cases, data may be combined to overcome limitations of a single
source. With care, data may be found that will produce generalizable findings for
the population of interest.
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OBJECTIVES: Gathering data tends to be an expensive and time consuming task.
During the IFEDH research project different methods for using routine data on
models in HTA were discussed, improved and developed. Connecting a rich dataset
from Austrias inpatient sector lacking patient identifiers and (kind of) personalized
but sparse records from the outpatient sector provided by different social security
institutions is the objective of this project. A detailed description of the setup and
usage of the results were presented at the SHIP Conference 2011 in St. Andrews
(http://www.scot-ship.ac.uk/conference-2011) and the International Data Linkage
Conference 2012 in Perth (http://www.datalinkage2012.com.au/). METHODS: Doc-
umentation of prior processing and information of the provided data were not fully
available and also questionable data quality and the presence of possible dupli-
cates result in technical and contextual challenges. After prepossessing, data qual-
ity assessment and other preparations, a deterministic record linkage approach
was developed using a combination of the open and freely available statistical
environment R and PostgreSQL database. Based on dynamically created SQL state-
ments and extensive logging, the linkage process can be enhanced easily if new
knowledge about the input data gets available. RESULTS: The resulting linked
dataset provides high quality and immediately available information. Additionally
the deterministic linkage process can be examined and understood by its users.
Therefore linkage and data errors are identified easily and feedback can be used to
enhance the overall result. These experiences also lay the foundation for more
advanced linkage methods and further improvements. CONCLUSIONS: After the
long and challenging way from the first data import to a functioning data collec-
tion, adequate information can now be used in different projects with low costs
and users confidence.
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OBJECTIVES:With introduction of AMNOG legislation, the pharmaceutical compa-
nies must submit a dossier when launching new drugs. The dossier must include
an estimate of number of patients to be treated. This is particularly challenging in
case of rare diseases, as shown with transthyretin-type familial amyloid polyneu-
ropathy (TTR-FAP). METHODS: Several sources were used for a comprehensive
gathering of information. Apart from systematic literature research, incidence data
was searched by internet research and within patient registers. Since current ther-
apy of choice is liver transplantation, the German Organ Transplantation Founda-
tion was consulted regarding frequency of liver transplantation in connection with
TTR-FAP. Assuming all patients are immediately placed on a waiting list after
diagnosis, the number of annually performed surgeries was equaled with the inci-
dence of the TTR-FAP. Results of this research were compared to billing data of a
national statutory health insurance. RESULTS: Given its European prevalence of
approx. 1.1/100,000, TTR-FAP is an ultra-orphan-disease. For endemic regions
(Sweden, Portugal) the disease is well captured and documented. For Germany, no
comparable published data is available. 5 national treatment centers were identi-
fied that document their patients in various registers, reflecting an incidence of
about 7 surgeries per year. According to the German Organ Transplantation Foun-
dation on average 6 new TTR-FAP patients per annum were added to the waiting
list, confirming the estimate of the incidence derived from registers. Domino trans-
plantation is usual in TTR-FAP with an average of 6.5 domino transplantations p.a.,
validating the estimate of an incidence of 6 – 7 patients per year. Billing data reflects
an estimated prevalence between 0.6 and 1.4/100,000. CONCLUSIONS: Data on the
prevalence of rare diseases frequently is not available or very unreliable. Different
sources produce strongly varying results due to several reasons. This must be taken
into account when assessing the number of patients in the value dossiers for new
drugs.
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OBJECTIVES: PROQOLID was developed in 2002 to provide all those involved in
health care evaluation with a comprehensive and unique source of information on
Patient-Reported Outcome (PRO) and Health-Related Quality of Life (HRQL) mea-
sures available through the Internet. The objective of this study is to review the
evolution of content, structure, and functionalities of PROQOLID since 2002.
METHODS: The archives of PROQOLID were searched to retrieve the database just
before its launch and to compare its content and structure as it was in April 2012.
RESULTS: The first database, then known as QOLID, was retrieved. It included 313
instruments (32 generic and 281 disease- or condition-specific). Instruments spe-
cific to oncology were the most frequent (54). The structure had three categories:
contact, conditions of use, and a copy of the questionnaire. By comparison, the
April 2012 database includes 714 instruments (128% increase, with 100 generic and
614 specific), with an increase of almost 40 instruments each year (up by 401 in 10
1/2 years). Instruments specific to nervous system diseases are the most frequent
(141), reflecting the evolution in the field (e.g., 76.7% of the neurological products
authorized by the EMA have been approved since 2002). The information displayed
for each instrument has been improved with the addition of five categories: trans-
lations available, descriptive information, content validity documentation, mea-
surement properties, references, and websites. In January 2005 the database was
renamed PROQOLID to reflect the wider use of the term PRO. In April 2012, a new
Google-type search engine was added to make browsing more user friendly. Soon
all users will have more information about instruments distributed by MAPI Re-
search Trust. CONCLUSIONS: In just over 10 years, the PROQOLID database has
considerably evolved in content and structure, and offers a range of information
and services adapted to the evolution of the field.
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OBJECTIVES: As part of consulting projects IMSCG performs 5000 payer inter-
views p.a. Interview analysis is typically focused on insights directly related to
research objectives. However, often respondents provide perceptions/ un-
prompted insights unrelated to research objectives, which have never been anal-
ysed before. The objective was to test whether information obtained from un-
prompted payer responses in interview write-ups can be identified and analysed,
to develop insights of payer perceptions of pharma and their impact on payer
decisions. METHODS: We selected 100 projects performed 2008-2011 including
double blinded interviews with national/regional payers/advisors, recorded in Eng-
lish in the IMSCG project database. Interviews were screened for quotes reflecting
perceptions of pharma unrelated to the research objective. Only unprompted ex-
pressions were extracted and buzz-words created that allowed compression into a
single word/phrase. Buzz-words were valued and categorized into perception clus-
ters (reputation, interaction, employees, portfolio and research) to identify the
cause of perceptions. Quotes linking perceptions directly to decisions were
mapped separately. Respondents’ function and geography were interlinked with
the information. RESULTS: We identified 543 interviews including 900 quotes with
unprompted expressions of perceptions in 1900 buzz-words. Distribution of inter-
views was equal between national/regional payers, but 80% of quotes came from
regional payers. Top5 EU accounted for majority of quotes. Company specific and
industry perceptions were evenly split. Data allows a variety of perception analysis:
national vs. regional payer, pharma vs. company, company perceptions of national
vs. regional payers. Perception clusters identify the cause of perceptions. Analysis
of the impact of perception on payer decisions is feasible, based on 5% of overall
quotes. CONCLUSIONS: The data allows a structured analysis of unprompted ex-
pressions of payer perceptions in retrospective research. Database processing is
ongoing to derive in the future statistically significant answers related to the im-
pact of payer perceptions on decisions and what these perceptions are based upon.
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